Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 9, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,449,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,562.50 pence per share; lowest price paid was 1,541 pence per share.
- Treasury Holdings (Settled): 490,129,412 shares (9.13% of total issued share capital).
- Treasury Holdings (Including Unsettled): 494,468,912 shares (10.14% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,875,990,152 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,449,000 shares on October 9, 2013. Consequently, the percentage of shares held in Treasury increased to 9.13% of issued capital and 10.14% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules regarding share ownership notifications.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (490,129,412 settled) against the company's latest capitalization table.
- Confirm the denominator for voting rights calculations is 4,875,990,152 shares (excluding treasury shares).
- Check if the 10.14% voting rights threshold (including unsettled shares) impacts any specific shareholder notification requirements under FCA rules.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim results for revenue and profit metrics.